PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Fampridine

Drugs in development · updated 30 October 2026

Fampridine: clinical trials and development status

Other names and codes: 4-Aminopyridine, Ampyra

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 20 July 2011

As of 30 October 2026 Fampridine is in 11 active clinical trials (recruiting or ongoing, phases I–III) for 14 diseases. The most advanced phase is III.

11Active trials
IIIMost advanced phase
14Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Fampridine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
AtaxiaIII1NCT07185347
DiplopiaIII1NCT07185347
Erectile dysfunctionII–III1NCT03701581
Multiple sclerosisIII1NCT06136728
Prostatic NeoplasmsII–III1NCT03701581
Wounds and InjuriesII2NCT06596434
BurnII1NCT06596434
Carpal tunnel syndromeII1NCT06294821
Crush InjuriesII1NCT06003166
Peripheral nerve injuryII1NCT06003166
Spinal cord injuryI–II1NCT06853015
Tomaculous neuropathyII1NCT06294821
Gastrointestinal stromal tumorI1NCT07171203
Vocal cord paresisI1NCT07832331

Everything on Fampridine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch